Literature DB >> 1682387

Rapid increases in the membrane expression of neutral endopeptidase (CD10), aminopeptidase N (CD13), tyrosine phosphatase (CD45), and Fc gamma-RIII (CD16) upon stimulation of human peripheral leukocytes with human C5a.

T Werfel1, G Sonntag, M H Weber, O Götze.   

Abstract

Rapid increases in the membrane expression of C3 receptors on granulocytes and monocytes in response to the anaphylatoxin C5a have previously been described. In this study we demonstrate increases in the membrane expression of neutral endopeptidase (NEP, CD10, CALLA), aminopeptidase N (APN, CD13), tyrosine phosphatase (CD45/CD45Ro) and the Fc R Fc gamma-RIII (CD16) on granulocytes within minutes of treatment with human C5a. Monocytes responded to C5a with increases in CD13 and CD45/CD45Ro. These membrane modulations could be prevented by preincubating the C5a preparations with anti-C5a mAb C17/5 but not by pretreating the cells with cycloheximide. Increases of CD10, CD13, and CD11b but not CD11a (LFA-1) were also observed in leukocytes from patients undergoing hemodialysis with cuprophan membranes. The increase of CD16 on granulocytes was dependent on the presence of plasma during in vitro activation with C5a indicating that plasma contains inhibitors which prevent the previously described loss of Fc gamma-RIII upon stimulation of the cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682387

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Different effects of steroidal therapy on neuropeptide-active enzymes in male and female human saliva.

Authors:  Federica Albo; Riccardo Antonangeli; Antonella Cavazza; Mario Marini; L Giorgio Roda; Paolo Rossi
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

2.  Flow cytometric study of neutrophilic granulopoiesis in normal bone marrow using an expanded panel of antibodies: correlation with morphologic assessments.

Authors:  M Tarek Elghetany; Yimin Ge; Jyoti Patel; Joe Martinez; Hanna Uhrova
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

3.  Effect of differentiation on the leucine enkephalin-degrading soluble enzymes released by the K562(S) cell line.

Authors:  M Marini; L Bongiorno; A Urbani; E Trani; L G Roda
Journal:  Neurochem Res       Date:  1997-12       Impact factor: 3.996

Review 4.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

Review 5.  Granules and secretory vesicles of the human neutrophil.

Authors:  N Borregaard; L Kjeldsen; K Lollike; H Sengeløv
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

6.  Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases.

Authors:  M H Wang; A Skeel; E J Leonard
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

7.  Rapid mitogen-induced aminopeptidase N surface expression in human T cells is dominated by mechanisms independent of de novo protein biosynthesis.

Authors:  U Lendeckel; T Wex; A Ittenson; M Arndt; K Frank; O Mayboroda; W Schubert; S Ansorge
Journal:  Immunobiology       Date:  1997-06       Impact factor: 3.144

8.  Up-regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2.

Authors:  Oliver Weinmann; Ralf Gutzmer; Jörg Zwirner; Miriam Wittmann; Katja Langer; Margarete Lisewski; Susanne Mommert; Alexander Kapp; Thomas Werfel
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

9.  Changes in monocytic expression of aminopeptidase N/CD13 after major trauma.

Authors:  G Huschak; K Zur Nieden; R Stuttmann; D Riemann
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

10.  Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.

Authors:  M Oppermann; O Götze
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.